BioDlink International Co (HKSE:01875) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01875 BioDlink International Co Ltd HKSE:01875
64 GF Score
Price HK$4.02
GF Value HK$1.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BioDlink International Co Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

BioDlink International Co's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HKSE:01875 vs VRTX, REGN, RVMD: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, BioDlink International Co's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioDlink International Co Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioDlink International Co's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where BioDlink International Co's Margin of Safety % (DCF Dividends Based) falls into.


HKSE:01875
64GF Score
BioDlink International Co Ltd HKSE:01875
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioDlink International Co (HKSE:01875) Overvalued in 2026?

Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued. The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47. GuruFocus considers BioDlink International Co to be Significantly Overvalued.

Key valuation signals for HKSE:01875:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioDlink International Co Business Description

Address 120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
64GF Score

Get the complete analysis for HKSE:01875

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.02
Price
HK$1.47
GF Value